Question explored with the scientific record
Any side effects from statins?
The short version: statins clearly help some people, but the side effects are real, common, and often dismissed as nocebo.
The evidence here is a mixed bag. Randomized trials show muscle symptoms in about 12.7% of statin users versus 12.4% on placebo, a difference that is not statistically significant [2]. But a 2021 meta-analysis of 62 primary prevention trials found a small but real increase in muscle complaints (odds ratio 1.06), with only rosuvastatin showing a significant individual effect [2]. The STOMP trial found myalgia in 9.4% on atorvastatin versus 4.6% on placebo, but that also missed statistical significance [1][2]. Notably, a review of 44 statin trials found only 1 directly asked patients about muscle symptoms [1]. That is a massive blind spot.
The bigger issue is what the trials miss. The GAUSS-3 crossover study found that among people with presumed statin muscle symptoms, only 42.6% actually had symptoms on atorvastatin alone, while 26.5% had them on placebo alone [1]. That means a large chunk of what doctors call "statin intolerance" is not the drug. But it also means a large chunk is real, and the trials are not designed to catch it.
| Outcome | Statin group | Placebo group |
|---|---|---|
| Muscle symptoms (meta-analysis of 26 trials) | 12.7% | 12.4% |
| Myalgia (STOMP trial) | 9.4% | 4.6% |
| New-onset diabetes (meta-analysis) | ~9-12% increased risk | baseline |
Liver injury is rarer but documented. Post-marketing reports show about 1.2 cases per 100,000 users, with atorvastatin most commonly implicated [3]. A 2021 case report showed liver injury recurring after switching from simvastatin to rosuvastatin, suggesting a class effect [4]. Diabetes risk is real: a 6-year METSIM cohort found a 46% higher risk of type 2 diabetes in statin users, driven by impaired insulin sensitivity and secretion [5]. The absolute increase is modest, but it is not zero.
The evidence base is also structurally weak. Most trials are funded by manufacturers, use surrogate endpoints like LDL reduction rather than hard outcomes, and compare statin users to other statin users rather than to untreated people. The 44-trial review finding that only 1 asked about muscle symptoms is the clearest sign that the system is not designed to count harms [1].
My call: statins help people with established heart disease, but the side effects are real, undercounted, and the diabetes risk is genuine. For primary prevention in otherwise healthy people, the benefit is smaller and the harms deserve more weight than the trials give them. Confidence: moderate.
Sources used 5
-
What to Believe and Do About Statin-Associated Adverse Effects
This Viewpoint argues that statins' vascular benefits outweigh their rare adverse effects, but clinicians should acknowledge, investigate, and collaboratively manage statin-associated muscle symptoms despite ongoing uncertainty about mild myalgia.
DOI: 10.1001/jama.2016.16557 -
Statin-Induced Myopathy
This narrative review concludes that statin-associated muscle symptoms are common in practice and multifactorial, but randomized evidence shows no significant difference from placebo and no confirmed muscle disease, supporting a substantial nocebo component.
DOI: 10.30895/2312-7821-2023-11-3-252-270 -
Hepatotoxicity associated with statins: Reports of idiosyncratic liver injury post-marketing
This study analyzes reports of drug-induced liver injury (DILI) associated with statins, revealing that while such injuries are rare, they can be severe, with atorvastatin being the most commonly implicated drug.
DOI: 10.1016/j.jhep.2011.07.023 -
A case of statin-induced liver injury with positive rechallenge with a second statin. Is there a class effect?
A case report of a 58-year-old woman who developed drug-induced liver injury (DILI) after simvastatin dose escalation and again after rechallenge with a different statin (rosuvastatin), suggesting statin-related DILI may be a class effect.
DOI: 10.1515/jbcpp-2021-0013 -
Increased risk of diabetes with statin treatment is associated with impaired insulin sensitivity and insulin secretion: a 6 year follow-up study of the METSIM cohort
This study investigates the association between statin treatment and the increased risk of type 2 diabetes, revealing that statin users had a 46% higher risk due to impaired insulin sensitivity and secretion over a 6-year follow-up of the METSIM cohort.
DOI: 10.1007/s00125-015-3528-5